Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 09, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result

Castle presented new data from the first independent validation of the recently published COOG2.1 study by Harbour et al. at ARVO 2025.
April 30, 2025 17:00 ET | Source: Castle Biosciences, Inc.

New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

Castle announced the publication of a new study demonstrating DecisionDx-Melanoma outperforms AJCC staging and the CP-GEP test.
December 12, 2023 07:57 ET | Source: Tome Biosciences

Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform

Tome Biosciences launches with over $200 million in funding to advance programmable genomic integration (PGI).
May 16, 2023 04:30 ET | Source: Data Bridge Market Research

Genomic Medicine Market is Probable to Influence the Value of USD 75.67 Billion by 2029, Size, Share, Trends, Demand, Growth, Challenges and Competitive Analysis

BOSTON, May 16, 2023 (GLOBE NEWSWIRE) -- Data Bridge Market Research's latest report, "Genomic Medicine Market" provides a thorough analysis of growth strategies, drivers, opportunities, key...
November 08, 2022 10:00 ET | Source: Experimental Biology and Medicine

Genomic transposable elements modify the progression of Parkinson's disease

WASHINGTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- A recently published article in Experimental Biology and Medicine (Volume 247, Issue 18, September, 2022) improves our understanding of genomic...
October 23, 2019 07:30 ET | Source: OpGen, Inc.

U.S. Patent Allowed Covering Acuitas Lighthouse® Software

GAITHERSBURG, Md., Oct. 23, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that the United States Patent and Trademark Office (the “USPTO”) has allowed a key OpGen patent...
September 18, 2019 07:30 ET | Source: OpGen, Inc.

OpGen Provides update on Curetis Group’s R&D Collaboration

Curetis R&D collaboration to develop NGS-based predictive antibiotic resistance testing powered by ARESdbCollaborator to fund R&D and obtains option to license ARESdb and ARES Technology...
September 08, 2016 07:30 ET | Source: OpGen, Inc.

OpGen, Inc. to Host Anti-Infectives Roundtable at the World Anti-Microbial Resistance Congress

GAITHERSBURG, Md., Sept. 08, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that it will participate in the World Anti-Microbial Resistance Congress being held September 8-9 in...
June 14, 2016 04:00 ET | Source: Elsevier, Inc.

Elsevier Publishes Medical Epigenetics, New Landmark Volume in Translational Epigenetics Series

CAMBRIDGE, MA--(Marketwired - June 14, 2016) - Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of Medical...